Synthesis of Chromene-linked Bis-indole Derivatives as Selective Tumor-associated Carbonic Anhydrase IX Inhibitors


Дәйексөз келтіру

Толық мәтін

Аннотация

Background:Sulfonamide derivatives are well-reported hCA IX inhibitors; however, they inhibit all types of hCA without any selectivity, leading to severe adverse effects. Hence, developing a novel nonsulfonamide class of tumor-associated hCA IX inhibitors through non-classical inhibition may provide greater selectivity and better pharmacokinetics.

Objective:The objective of this study was to develop non-sulfonamide derivatives as potential human carbonic anhydrase (hCA) inhibitors and develop a new series of chromene-linked bis-indole derivatives.

Methods:We synthesized and characterized the chromene-linked bis-indole derivatives and further evaluated them against four hCA isoforms, i.e., hCA I, hCA II, hCA IX, and hCA XII, and determined the ADMET parameters by the In-silico method.

Results:Most of the compounds showed significantly greater affinity and selectivity towards the tumorassociated hCA IX over other hCA isoforms within the lower micromolar to submicromolar range. In particular, the bromo-substituted bis-indole derivative 6t showed an excellent inhibition of hCA IX isoform with an affinity (Ki) of 2.61 μM. In contrast, the cyano group substituted bis-indole derivative 6s and also displayed a strong inhibition of hCA IX isoform with an affinity (Ki) of 2.73 μM. Many other potential candidates, including 6g, 6i, 6k, 6m, 6o, 6p, and 6r, showed higher affinity at tumor-associated hCA IX with lower than 10 μM compared to other hCA isoforms.

Conclusion:Therefore, the chromene-linked bis-indole derivatives can serve as a novel non-sulfonamide class of tumor-associated hCA IX inhibitors.

Авторлар туралы

Priti Singh

Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Sridhar Nerella

Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

Baijayantimala Swain

Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

Andrea Angeli

Neurofarba Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenz

Email: info@benthamscience.net

Samreen Kausar

Chemistry Section, School of Sciences,, Maulana Azad National Urdu University (MANUU),

Email: info@benthamscience.net

Qasim Ullah

Chemistry Section, School of Sciences, Maulana Azad National Urdu University (MANUU),

Email: info@benthamscience.net

Claudiu Supuran

Neurofarba Department, Sezione di Scienze Farmaceutiche e Nutraceutiche,, Università degli Studi di Firenze

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Mohammed Arifuddin

Department of Medicinal Chemistry,, National Institute of Pharmaceutical Education and Research (NIPER),

Email: info@benthamscience.net

Әдебиет тізімі

  1. Ganesh, K.; Massagué, J. Targeting metastatic cancer. Nat. Med., 2021, 27(1), 34-44. doi: 10.1038/s41591-020-01195-4 PMID: 33442008
  2. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249. doi: 10.3322/caac.21660 PMID: 33538338
  3. Wang, X.; Zhang, H.; Chen, X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist., 2019, 2(2), 141-160. doi: 10.20517/cdr.2019.10 PMID: 34322663
  4. Anand, U.; Dey, A.; Chandel, A.K.S.; Sanyal, R.; Mishra, A.; Pandey, D.K.; De Falco, V.; Upadhyay, A.; Kandimalla, R.; Chaudhary, A.; Dhanjal, J.K.; Dewanjee, S.; Vallamkondu, J.; Pérez de la Lastra, J.M. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis., 2023, 10(4), 1367-1401. doi: 10.1016/j.gendis.2022.02.007 PMID: 37397557
  5. Nerella, S.G.; Thacker, P.S.; Arifuddin, M.; Supuran, C.T. Tumor associated carbonic anhydrase inhibitors: Rational approaches, design strategies, structure activity relationship and mechanistic insights. Eur. J. Med. Chem. Reports, 2024, 10, 100131. doi: 10.1016/j.ejmcr.2024.100131
  6. Nerella, S.G.; Singh, P.; Arifuddin, M.; Supuran, C.T. Anticancer carbonic anhydrase inhibitors: A patent and literature update 2018-2022. Expert Opin. Ther. Pat., 2022, 32(8), 833-847. doi: 10.1080/13543776.2022.2083502 PMID: 35616541
  7. Aggarwal, M.; Boone, C.D.; Kondeti, B.; McKenna, R. Structural annotation of human carbonic anhydrases. J. Enzyme Inhib. Med. Chem., 2013, 28(2), 267-277. doi: 10.3109/14756366.2012.737323 PMID: 23137351
  8. Kakakhan, C.; Türkeş, C.; Güleç, Ö.; Demir, Y.; Arslan, M.; Özkemahlı, G.; Beydemir, Ş. Exploration of 1,2,3-triazole linked benzenesulfonamide derivatives as isoform selective inhibitors of human carbonic anhydrase. Bioorg. Med. Chem., 2023, 77, 117111. doi: 10.1016/j.bmc.2022.117111 PMID: 36463726
  9. Thacker, P.S.; Mohammed, A.; Supuran, C.T.; Tiwari, P.L.; Goud, N.S.; Srikanth, D.; Angeli, A. Synthesis and biological evaluation of coumarin carboxamides as selective and potent inhibitors of carbonic anhydrases IX and XII. Anticancer. Agents Med. Chem., 2022, 22(14), 2647-2654. doi: 10.2174/1871520622666220304184525 PMID: 35249507
  10. Singh, P.; Kumar, S.D.; Sridhar, G.N.; Swain, B.; Kumar, S.S.; Angeli, A.; Shaik, A.B.; Madhavi, Y.V.; Supuran, C.T.; Arifuddin, M. Ureidosulfocoumarin derivatives as selective and potent carbonic anhydrase ix and xii inhibitors. ChemMedChem, 2022, 17(5), e202100725. doi: 10.1002/cmdc.202100725 PMID: 34898017
  11. Chandra, K.M.; Goud, N.S.; Arifuddin, M.; Alvala, M.; Alvala, R.; Angeli, A.; Supuran, C.T. Synthesis and biological evaluation of novel 4,7-disubstituted coumarins as selective tumor-associated carbonic anhydrase IX and XII inhibitors. Bioorg. Med. Chem. Lett., 2021, 39, 127877. doi: 10.1016/j.bmcl.2021.127877 PMID: 33640442
  12. Supuran, C.T. Multi- and poly-pharmacology of carbonic anhydrase inhibitors. Pharmacol. Rev., 2024. Epub ahead of print doi: 10.1124/pharmrev.124.001125
  13. Awadallah, F.M.; Bua, S.; Mahmoud, W.R.; Nada, H.H.; Nocentini, A.; Supuran, C.T. Inhibition studies on a panel of human carbonic anhydrases with N 1-substituted secondary sulfonamides incorporating thiazolinone or imidazolone-indole tails. J. Enzyme Inhib. Med. Chem., 2018, 33(1), 629-638. doi: 10.1080/14756366.2018.1446432 PMID: 29536779
  14. Singh, P.; Sridhar, G.N.; Swain, B.; Kumar, S.S.; Choli, A.; Angeli, A.; Singh, K.B.; Madhavi, Y.V.; Supuran, C.T.; Arifuddin, M. Synthesis of a new series of quinoline/pyridine indole-3-sulfonamide hybrids as selective carbonic anhydrase IX inhibitors. Bioorg. Med. Chem. Lett., 2022, 70, 128809. doi: 10.1016/j.bmcl.2022.128809 PMID: 35605838
  15. Bonardi, A.; Nocentini, A.; Bua, S.; Combs, J.; Lomelino, C.; Andring, J.; Lucarini, L.; Sgambellone, S.; Masini, E.; McKenna, R.; Gratteri, P.; Supuran, C.T. Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: Improving ligand/isoform matching and selectivity of action. J. Med. Chem., 2020, 63(13), 7422-7444. doi: 10.1021/acs.jmedchem.0c00733 PMID: 32519851
  16. Angeli, A.; Kartsev, V.; Petrou, A.; Pinteala, M.; Brovarets, V.; Vydzhak, R.; Panchishin, S.; Geronikaki, A.; Supuran, C.T. Carbonic anhydrase inhibition with sulfonamides incorporating pyrazole- and pyridazinecarboxamide moieties provides examples of isoform-selective inhibitors. Molecules, 2021, 26(22), 7023. doi: 10.3390/molecules26227023 PMID: 34834114
  17. Kerru, N.; Gummidi, L.; Maddila, S.; Gangu, K.K.; Jonnalagadda, S.B. A review on recent advances in nitrogen-containing molecules and their biological applications. Molecules, 2020, 25(8), 1909. doi: 10.3390/molecules25081909 PMID: 32326131
  18. Heravi, M.M.; Zadsirjan, V. Prescribed drugs containing nitrogen heterocycles: An overview. RSC Advances, 2020, 10(72), 44247-44311. doi: 10.1039/D0RA09198G PMID: 35557843
  19. Kaushik, N.; Kaushik, N.; Attri, P.; Kumar, N.; Kim, C.; Verma, A.; Choi, E. Biomedical importance of indoles. Molecules, 2013, 18(6), 6620-6662. doi: 10.3390/molecules18066620 PMID: 23743888
  20. Peerzada, M.N.; Khan, P.; Ahmad, K.; Hassan, M.I.; Azam, A. Synthesis, characterization and biological evaluation of tertiary sulfonamide derivatives of pyridyl-indole based heteroaryl chalcone as potential carbonic anhydrase IX inhibitors and anticancer agents. Eur. J. Med. Chem., 2018, 155, 13-23. doi: 10.1016/j.ejmech.2018.05.034 PMID: 29852328
  21. Güzel, Ö.; Maresca, A.; Scozzafava, A.; Salman, A.; Balaban, A.T.; Supuran, C.T. Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII. Bioorg. Med. Chem. Lett., 2009, 19(11), 2931-2934. doi: 10.1016/j.bmcl.2009.04.068 PMID: 19410461
  22. Mohsin, N.A.; Irfan, M.; Hassan, S.; Saleem, U. Current strategies in development of new chromone derivatives with diversified pharmacological activities: A review. Pharm. Chem. J., 2020, 54(3), 241-257. doi: 10.1007/s11094-020-02187-x PMID: 32836513
  23. Patil, V.M.; Masand, N.; Verma, S.; Masand, V. Chromones: Privileged scaffold in anticancer drug discovery. Chem. Biol. Drug Des., 2021, 98(5), 943-953. doi: 10.1111/cbdd.13951 PMID: 34519163
  24. Alneyadi, A.; Nizami, Z.N.; Aburawi, H.E.; Hisaindee, S.; Nawaz, M.; Attoub, S.; Ramadan, G.; Benhalilou, N.; Al Azzani, M.; Elmahi, Y.; Almeqbali, A.; Muhammed, K.; Eid, A.H.; Vijayan, R.; Iratni, R. Synthesis of new chromene derivatives targeting triple-negative breast cancer cells. Cancers (Basel), 2023, 15(10), 2682. doi: 10.3390/cancers15102682 PMID: 37345018
  25. Raj, V.; Lee, J. 2H/4H-chromenes—A versatile biologically attractive scaffold. Front Chem., 2020, 8, 623. doi: 10.3389/fchem.2020.00623 PMID: 32850645
  26. Angeli, A.; Kartsev, V.; Petrou, A.; Pinteala, M.; Brovarets, V.; Slyvchuk, S.; Pilyo, S.; Geronikaki, A.; Supuran, C.T. Chromene-containing aromatic sulfonamides with carbonic anhydrase inhibitory properties. Int. J. Mol. Sci., 2021, 22(10), 5082. doi: 10.3390/ijms22105082 PMID: 34064890
  27. Sequeira, L.; Distinto, S.; Meleddu, R.; Gaspari, M.; Angeli, A.; Cottiglia, F.; Secci, D.; Onali, A.; Sanna, E.; Borges, F.; Uriarte, E.; Alcaro, S.; Supuran, C.T.; Maccioni, E. 2H-chromene and 7H-furo-chromene derivatives selectively inhibit tumour associated human carbonic anhydrase IX and XII isoforms. J. Enzyme Inhib. Med. Chem., 2023, 38(1), 2270183. doi: 10.1080/14756366.2023.2270183 PMID: 37870190
  28. Kostopoulou, I.; Tzani, A.; Polyzos, N.I.; Karadendrou, M.A.; Kritsi, E.; Pontiki, E.; Liargkova, T.; Hadjipavlou-Litina, D.; Zoumpoulakis, P.; Detsi, A. Exploring the 2′-Hydroxy-Chalcone framework for the development of dual antioxidant and soybean lipoxygenase inhibitory agents. Molecules, 2021, 26(9), 2777. doi: 10.3390/molecules26092777 PMID: 34066803
  29. Feng, L.; Maddox, M.M.; Alam, M.Z.; Tsutsumi, L.S.; Narula, G.; Bruhn, D.F.; Wu, X.; Sandhaus, S.; Lee, R.B.; Simmons, C.J.; Tse-Dinh, Y.C.; Hurdle, J.G.; Lee, R.E.; Sun, D. Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives. J. Med. Chem., 2014, 57(20), 8398-8420. doi: 10.1021/jm500853v PMID: 25238443
  30. Rocha, D.H.A.; Batista, V.F.; Balsa, E.J.F.; Pinto, D.C.G.A.; Silva, A.M.S. Chromene- and quinoline-3-carbaldehydes: Useful intermediates in the synthesis of heterocyclic scaffolds. Molecules, 2020, 25(17), 3791. doi: 10.3390/molecules25173791 PMID: 32825385
  31. Thacker, P.S.; Sridhar, G.N.; Argulwar, O.S.; Soman, J.; Angeli, A.; Alvala, M.; Arifuddin, M.; Supuran, C.T. Synthesis and biological evaluation of some coumarin hybrids as selective carbonic anhydrase IX and XII inhibitors. Bioorg. Chem., 2020, 104, 104272. doi: 10.1016/j.bioorg.2020.104272 PMID: 32961467
  32. Bakchi, B.; Krishna, A.D.; Sreecharan, E.; Ganesh, V.B.J.; Niharika, M.; Maharshi, S.; Puttagunta, S.B.; Sigalapalli, D.K.; Bhandare, R.R.; Shaik, A.B. An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist’s perspective. J. Mol. Struct., 2022, 1259, 132712. doi: 10.1016/j.molstruc.2022.132712
  33. Bozdag, M.; Ferraroni, M.; Carta, F.; Vullo, D.; Lucarini, L.; Orlandini, E.; Rossello, A.; Nuti, E.; Scozzafava, A.; Masini, E.; Supuran, C.T. Structural insights on carbonic anhydrase inhibitory action, isoform selectivity, and potency of sulfonamides and coumarins incorporating arylsulfonylureido groups. J. Med. Chem., 2014, 57(21), 9152-9167. doi: 10.1021/jm501314c PMID: 25310626
  34. Akdemir, A.; De Monte, C.; Carradori, S.; Supuran, C.T. Computational investigation of the selectivity of salen and tetrahydrosalen compounds towards the tumor-associated hCA XII isozyme. J. Enzyme Inhib. Med. Chem., 2015, 30(1), 114-118. doi: 10.3109/14756366.2014.892936 PMID: 24666302
  35. Supuran, C.T.; Barboiu, M.; Luca, C.; Pop, E.; Brewster, M.E.; Dinculescu, A. Carbonic anhydrase activators. Part 14. Syntheses of mono and bis pyridinium salt derivatives of 2-amino-5-(2-aminoethyl)- and 2-amino-5-(3-aminopropyl)-1,3,4-thiadiazole and their interaction with isozyme II. Eur. J. Med. Chem., 1996, 31(7-8), 597-606. doi: 10.1016/0223-5234(96)89555-9

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2025